Omapatrilat

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Omapatrilat
Omapatrilat.svg
Clinical data
ATC code
  • None
Legal status
Legal status
  • Development terminated
Identifiers
Synonyms BMS-186716
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C19H24N2O4S2
Molar mass 408.534 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Omapatrilat (INN,[1] tentative trade name Vanlev) is an antihypertensive agent that inhibits both neprilysin (neutral endopeptidase, NEP) and angiotensin-converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling.

This drug from Bristol-Myers Squibb was not approved by the U.S. Food and Drug Administration due to angioedema safety concerns.[2]

Omapatrilat angioedema was attributed to its dual mechanism of action, inhibiting both angiotensin-converting enzyme (ACE), and neprilysin (neutral endopeptidase), both of these enzymes are responsible for the metabolism of bradykinin which causes vasodilation, angioedema, and airway obstruction.

Clinical uses[edit]

The drug was promoted for possible uses in congestive heart failure.

See also[edit]

References[edit]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 40" (PDF). World Health Organization. p. 190. Retrieved 2 March 2017. 
  2. ^ Venugopal, J (2 March 2005). "Pharmacological Modulation of the Natriuretic Peptide System". Expert Opinion on Therapeutic Patents. 13 (9): 1389–1409. doi:10.1517/13543776.13.9.1389. 

Further reading[edit]